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ABSTRACT 
 
Among females endometrial carcinoma is the  most frequent  malignancy 
worldwide . It is the second most frequent malignancy of gynecological tract in 
developing nations having an incidence of approximately six cases per one lakh 
population. Thyroid transcription factor  is a Deoxy ribonuclease  protein 
determined by the gene placed on chromosome 14q13.It has been regarded as a 
specific  and sensitive marker for tumors arising in thyroid and lung. This study is 
undertaken to  probe Thyroid transcription factor positivity in primary uterine 
endometrial adenocarcinoma  and also in malignant mixed mullerian tumour . 
 
AIMS AND OBJECTIVES:  
To study the incidence and distribution  of Thyroid transcription factor in  
endometrial adenocarcinoma. To correlate the percentage of expression of TTF-1 
with the grade of endometrial adenocarcinoma .And to assess the prognosis based 
on the expression of TTF-1 for the patients who were on follow up. 
 
MATERIALS AND  METHODS:   
93  cases  Paraffin  sections  of hysterectomy specimens diagnosed as 
Endometrial carcinoma will be subjected to routine H&Estaining and IHC  marker 
TTF1 was done for 50 random cases. 
 
RESULTS:  
Among 50  randomly selected cases  TTF 1 marker was done ,only 3 cases 
showed positivity for TTF 1. Two cases of  moderately differentiated 
endometrioid carcinoma were focally positive and one case of  poorly
differentiated carcinoma was diffusely positive for TTF 1 ,all others were 
negative.The relationship between  TTF 1 positivity and grade of endometrioid 
carcinoma has a pvalue of 0.004 which is statistically significant. 
 
CONCLUSION:  
In our study the incidence of  different types  of  endometrial carcinoma  in 
the 5 years from January 2010 to December 2014 in the Institute of Obstetrics and 
Gynecology, Madras  Medical College ,Chennai was studied. This study confirms  
that TTF 1 positivity correlates with grade of endometrial carcinoma. Out of the 3 
positive cases ,the follow up for 7 months  was available for only case of  stage I 
low grade endometrioid carcinoma  and  the comment on prognosis can only be 
made on long term followup. 
 
Keywords: Endometrial adenocarcinoma,Thyroid transcription factor 
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INTRODUCTION 
Among females endometrial carcinoma is the most frequent malignancy 
worldwide[1]. Each year  about  one lakh fifty thousand cases are diagnosed 
world wide[2,3].It is the second most frequent malignancy of gynecological tract 
in developing nations having an incidence of approximately six cases per one 
lakh  population.[4,5].The mean age for the occurrence of endometrial carcinoma 
is  between the age range of fifty to sixty years. 
Endometrial carcinoma  is classified broadly in to two categories  TYPE 
I  and TYPE II. Estrogen stimulation is strongly associated with TYPE 1 
carcinoma. In TYPE II carcinoma  mostly postmenopausal women are affected 
whereas  in TYPE I both premenopausal and postmenopausal women are 
involved. Mostly TYPE I tumors are low grade , TYPE II tumors are associated 
with high grade tumors. 
The main features of  prognosis of endometrial adenocarcinomas 
depends tumor  on type, stage and grade[6]. 
Thyroid transcription factor (TTF-1) immunostain is typically associated 
with lung and thyroid malignancies. Some studies have stated its positivity in 
endometrial carcinomas ,also in ovarian and cervical carcinomas[6,7,8].  
Thyroid transcription factor  is a Deoxy ribonuclease  protein 
determined by the gene placed on chromosome 14q13.It has been regarded as a 
specific  and sensitive marker for  tumors arising  in thyroid and lung[6].  
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In recent times  TTF-1 positivity  has been found  in other carcinomas of 
gynecologic origin including ovary,endometrium and  uterine cervix [6,7,8]. 
This study is undertaken to probe Thyroid transcription factor positivity 
in primary uterine endometrial adenocarcinoma  and also in malignant mixed 
mullerian tumour . 
 
 
 
 
 
 
 
 
 
 
 
                          
 
 
  
 
AIMS  
AND  
OBJECTIVES 
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AIMS AND OBJECTIVES 
3)  To assess the prognosis based on the expression of TTF-1 for the patients 
who were on follow up. 
 
 
 
 
 
 
 
 
                              
 
                         
 
1) To study the incidence and distribution  of Thyroid transcription factor in  
endometrial adenocarcinoma.  
2) To correlate the percentage of expression of TTF-1 with the grade of 
endometrial adenocarcinoma. 
  
 
REVIEW  
OF  
LITERATURE 
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REVIEW   OF LITERATURE 
 
Embryology and  Anatomy: 
Endometrium and myometrium  are  created by union  of   mullerian 
ducts between eighth  and  ninth  postovulatory weeks. They are of mesodermal  
in origin.  
At about  20th gestational week ,the surface epithelium invaginates in to 
the stroma to form glandular structures. 
In the prepubertal years ,endometrium is not active. But during 
reproductive years the endometrium undergoes cyclic morphologic changes. 
The uterus of a nulliparous women is  pear shaped, hollow  measuring   
around  seven to eight centimetre along its long axis  and weighs about 40 to 80 
grams. Whereas  multigravid  uterus  is   larger in weight and  it’s  length  
varies with increasing  parity. 
Uterine  corpus  is triangular in shape. It’s divided in to three parts the 
fundus, body and  isthumus. It is  lined  by endometrial   mucosa, which  
consists of  inner  layer of  endometrium  and  thick  muscular myometrium.  
Endometrial mucosa consists of endometrial glands and stroma. It can 
be divided into basal reserve layer and the superficial functional layer. 
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ENDOMETRIAL CARCINOMA 
Epidemiology and Incidence: 
Endometrial carcinoma  is the frequent  malignancy of female genital 
system. Its incidence is high in developed nations[9],being 4th  common 
carcinoma  in females[1]. 
Approximately 2 lakh eighty thousand new cases are diagnosed each 
year worldwide. Accounts for seven percent of invasive cancer in women. 
Most cases over 90 percent occur in females elder than 50 years of age. 
Occurrence most common in menopausal women [1], but  it can be found  at 
any age. 
Generally endometrial carcinoma produces symptoms by which it can 
be diagnosed at an early stage. The five year survival rate is higher in 
developed countries when compared to developing or underdeveloped  
nations[10,11]. 
About two percent of all cancer mortality in women is due to 
endometrial carcinoma[12]. 
 
Pathogenesis: 
Endometrial cancer can be classified in to 2 categories based upon 
clinicopathological and molecular genetic features as  
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1) Type I 
2) Type II 
 
Type I : 
It is the most common subtype, eighty percent occurs due to excess 
estrogen stimulation. It develops in the background of endometrial hyperplasia. 
But it can also arise denovo[13,14,15,16]. 
They are well differentiated and they closely resemble proliferative 
endometrial glands, so they are referred as Endometrioid carcinoma. 
      Women at risk are generally, 
¾ Obese 
¾ Hypertensive 
¾ Diabetic 
¾ Nulliparous /infertility 
¾ PCOD/stein leventhal syndrome 
¾ Tamoxifen treated breast cancer patients 
¾ Ovarian tumors – granulosa cell tumors 
and thecomas [17,18,19]. 
¾ Dysfunctional uterine bleeding patients 
on estrogen therapy 
The tumors under this category are not so aggressive. The carcinomas 
included under it are endometrioid carcinoma grade one and grade two.[20] 
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Britton LA et al studies have shown increased   estrogen levels in the 
serum of   patients having  endometrial cancer[21,22]. 
 
Type II: 
This type is not associated with hormones  and  also hyperplasia[23]. 
Serous type carcinoma  the most common type in this category. Other 
histological type included in this category is clear cell carcinoma, MMMT, 
undifferentiated carcinoma. 
It is not associated with estrogenic influence. Endometrial atrophy is 
usually associated with it. They are poorly differentiated tumors accounting for  
15 percent  of cases . 
The tumors are serous, clear cell type, MMMT, grade 3 endometrioid  
and undifferentiated carcinoma.[20] 
 
Etiology: 
1) Age: 
The risk of endometrial carcinoma increases  with advancing age[24]. 
Incidence is high in women who are postmenopausal usually the age 
range is between fifty five to sixty years. Incidence of endometrial 
carcinoma is unusual in women aged less than forty years. 
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2) Hormonal stimulation: 
Current studies  have found that unopposed estrogen therapy is 
associated with increased risk endometrial carcinoma[25,28,29]. 
Breast cancer Patients on long term treatment with tamoxifen have an 
increased  risk up to six to eight fold of development of endometrial 
carcinoma .[26,27] 
Women with excess endogenous estrogen exposure like  
¾ Early menarche 
¾ Late menopause 
¾ Tamoxifen therapy , 
¾  Nulliparous 
¾ PCOD 
¾ Infertility due anovulation are at increased risk[26,27]. 
 
3) Constitutional factors: 
Obesity  is a well defined risk factor for development of  endometrial 
carcinoma[31].It  is due augmented availability of peripheral estrogens 
converting into androgens[30].. 
 Other risk factor is Diabetes [21,2,3]. 
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4)Irradiation: 
Endometrial carcinoma  mainly  serous type has an association with 
pelvic irradiation ,but whether it’s spontaneous or radiation induced is not 
clear[32,37,39]. 
 
5)Diet: 
 Increase in total calorie intake along with  decreased  physical       
activity  is associated with elevated risk .    
 
6)Hereditary : 
About 10 percent of endometrial cancers are hereditary while most  are 
sporadic. 
HNPCC  patients have elevated  risk [33,34].They manifest with 
endometrial carcinoma at an younger age, majority of which are high grade non 
endometrioid carcinomas[35]. 
McCarty et al stated that individuals with gonadal dysgenesis like 
Turnor’s syndrome  have a propensity to develop well differentiated 
endometrial adenocarcinoma. Out of  thirteen cases that were studied ,eleven 
cases had received  estrogen therapy for protracted duration[36]. 
So whether Turner phenotype or unopposed estrogen therapy  for 
causation of endometrial adenocarcinoma  is vague. 
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Other syndromes associated with endometrial carcinoma are  
 
¾ Lynch syndrome:  
Its due to defective DNA mismatch  repair  genes-MLH 1, MSH6 , 
MSH2,PMS2. The inheritance pattern is of autosomal dominant type. Most 
HNPCC tumors are of endometrioid type but other type like serous,clear cell, 
MMMT and undifferentiated tumors also occur in this group[38]. 
Immunohistochemical studies with MLH1 and MSH2 antibodies have a 
sensitivity rate of about sixty nine percent and specificity of hundred percent[40]. 
 
¾ Cowden syndrome: 
Caused due to mutations in PTEN tumor suppressor gene. It is an autosomal 
dominant disorder. Patients have an increased risk of breast, endometrium and 
thyroid malignancies.The risk of endometrial carcinoma varies between 5 to 10 
percent compared to 2.6 percent risk in general population. 
According to Nelen MR et al  the histologic type has not been found[41]. 
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MOLECULAR GENETICS:   
ENDOMETRIOID  CARCINOMA: 
Development of Endometrial carcinoma  involves acquisition of several 
genetic alterations in tumor suppressor  and oncogenes .The most common 
altered gene is the PTEN (30-54% ) of cases[42]. 
Genomic sequencing of Type I endometrioid carcinoma have shown that 
most common mutations are those that increase the signaling  through 
PI3/AKT  pathway.AKT  is  abnormal  in cancer pathogenesis. 
The association of PTEN change in atypical and nonatypical hyperplasia 
is approximately 20 – 48 percent [43,44],which supports the view that atypical 
hyperplasia is the predecessor to carcinoma . 
 Oncogene PIK3CA  mutations are present in about 39  percent  of 
carcinoma, also in all tumor grades[45]. Thus the roles of PTEN  and PIK3CA 
mutations in endometriod carcinoma  are different , the former helps  for 
endometrial hyperplasia development , while the latter has  a role in conversion  
of complex atypical hyperplasia to cancer. 
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P53:  
 P53 mutations are found in 10 percent of all endometrioid carcinoma 
most common in grade 3 tumor, intermittedly in grade 2 tumors. 
They are not identified in grade 1 tumors which suggests  that they have 
a role in progression, but not in initiation of endometrioid carcinoma[46]. 
 
MICROSATELLITE INSTABILITY: 
Found in women with HNPCC  syndrome in which  the most common 
non colorectal malignancy is endometrial carcinoma[47]. 
Occurrence of microsatellite instability is approximately 20 percent in 
sporadic endometrial  cancers ,seen also in atypical  hyperplasia  that are 
associated with cancer. Most common mutated gene in sporadic microsatellite 
instability  is MLH1 gene[48,49,50]. 
 
KRAS : 
Studies indicate that K-RAS mutations are seen in 10 – 30 percent  of 
endometrial cancer[51,52,53]..It has been identified in all grades of endometrioid 
carcinoma and also in complex atypical hyperplasia. 
Overexpression of EGFR,HER2NEU,BCL2 ,FGFR2,CTNNB1 have 
been identified[54,55,56]. 
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SEROUS CARCINOMA: 
More than ninety percent of cases show P53 mutation [57,58]. About 75 
percent of Endometrial  intra epithelial neoplasia – precursor  lesion for serous 
carcinoma have P53 mutations[58]. 
Fifteen percent of these tumors have PIK3CA mutations suggesting role 
of PI3K/PTEN/AKT pathway in these tumors[59]. 
In serous carcinoma P53  mutations has  early incidence, in contrast to   
endometrioid carcinoma in which  poorly differentiated  endometrioid 
carcinoma, which has  aggressive behavior of these tumors[60]. 
To sum up molecular studies of two types of endometrial carcinomas 
indicate that these tumors often develop from precursors with addition  of 
genetic alterations. 
In serous carcinoma P53 mutations is associated with the alteration  of  
atrophic endometrium to serous intraepithelial  carcinoma which on further 
genetic alterations leads to invasive malignancy. 
 
PRECURSOR LESIONS  TO ENDOMETRIAL CARCINOMA: 
Endometrial hyperplasia  is the precursor lesion for development of 
endometrioid carcinoma. 
 It is associated with prolonged estrogenic stimulation of endometrial 
stimulation, which can be due obesity,  nulliparity, exogenous estrogen. 
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Classification : 
Classification proposed  by WHO  proposed by kurman and Norris [61]. 
Four categories : 
¾ Simple hyperplasia without atypia  
¾ Complex hyperplasia without atypia 
¾ Simple hyperplasia with atypia 
¾ Complex hyperplasia with atypia 
 
But current WHO classification clubs these four types in to two major 
categories 
¾ Non atypical hyperplasia 
¾ Atypical hyperplasia[EIN]. 
Clinical features: 
    Women usually present with irregular bleeding or found incidentally 
in biopsy workup done for infertility cases. The bleeding is profuse in 
women with endometrial hyperplasia or endometrial carcinoma when 
compared to spotty bleeding in atrophic endometrium. 
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Gross features: 
It may have a velvety or a spongy appearance . Although diffuse 
endometrial thickening  is common, a polypoidal appearance is also noted. 
Histological pattern is considered as a prerequisite for diagnosis of 
endometrial hyperplasia. 
 
NON ATYPICAL HYPERPLASIA: 
Characterized  by abnormal architechtural patterns with increased gland 
to stroma ratio. 
 
Simple hyperplasia without atypia: 
The stroma is abundant with cystic dilatations of endometrial glands. 
Cells are stratified ,with columnar morphology and  amphophilic cytoplasm  
and variable mitotic activity. Stromal cells are spindle and densely packed. 
 
Complex hyperplasia without atypia: 
Consists of complex ,branched irregular glands with back to back 
arrangement  and scant stroma. Stratification of cells in glands varies from 
2 to 4 layers,usually with variable mitotic activity. Stromal cells are spindle  
and are usually compressed by endometrial glands. 
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Nuclear features : 
Nuclear features in both types , are usually basally oriented oval bland 
similar to proliferative glands. 
Associated with estrogenic  stimulation. 
 
ATYPICAL HYPERPLASIA: 
Composed of complex patterns of proliferating glands and  nuclear 
atypia. 
The nuclei are stratified, shows loss of polarity and also an elevated 
nuclear and cytoplasmic ratio. Nucleus is round and have a vesicular 
appearance. 
Architectural features are the same in atypical and non atypical 
hyperplasia. 
About 23 to 48 percent of  atypical hyperplasia on endometrial sampling  
present with  carcinoma when hysterectomy is done. 
The criteria for distinguishing grade 1 endometrioid   carcinoma and 
atypical hyperplasia depends with the  identification of stromal invasion  by 
these features 
• Desmoplastic stroma with irregular gland infiltration 
• Widespread papillary pattern 
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• Cribriform pattern with confluent glands. 
 
Molecular genetics: 
     Microsatellite instability, PTEN  mutation and KRAS mutation are 
identified. 
      Relationship  with carcinoma:  
Progression to adenocarcinoma is approximately two percent in 
nonatypical hyperplasia. According to a study incidence of carcinoma 
following simple hyperplasia   is less than 0.4 percent[62]. 
Conversely incidence  of carcinoma with  atypical hyperplasia  is about 
15 to 30 percent [63,64,65,66].About eight percent in simple hyperplasia with 
atypia and twenty nine percent in complex hyperplasia with atypia. 
It was noted that most atypical hyperplasia regressed spontaneously 
when compared to atypical hyperplasia[66]. 
According to Mittal et al occurrence  of endometrial cancer  insitu  in 
complex atypical hyperplasia has elevated  incidence of  endometrial 
adenocarcinoma in  hysterectomy[67]. 
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Management  : 
In premenopausal women, conservative approach  with regular follow 
up if the  women have nonatypical hyperplasia .In women with atypical 
hyperplasia  progestin suppression can be done. 
In perimenopausal women, progestin treatment with regular endometrial 
biopsies  or hysterectomy can be done. 
In post menopausal women, the risk of carcinoma is huge hysterectomy 
is preferred if atypical hyperplasia is diagnosed. If the patient has surgical  
threat then continuous progestin therapy can be advocated. 
 
      ENDOMETRIAL INTRAEPITHELIAL CARCINOMA: 
It is the forerunner  for serous cancer.It is also known as carcinoma in 
situ. Not associated with estrogenic stimulation, occurring in the 
background of endometrial atrophy.  
Morphologically consists of cells with atypical nuclei lining the surface 
and endometrial glands  in an atrophic endometrium. 
       
Molecular genetics: 
Associated with P53 mutation. Also there is loss of heterozygosity at 
chromosome 17p. 
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      Management : 
Patients are  managed by hysterectomy. 
 
  ENDOMETRIAL ADENOCARCINOMA: 
It is the malignant tumor showing  glandular differentiation ,with 
infiltration   in to myometrium.   
More than 80 percent of endometrial tumor belong to Type I. 
Age group affected are Postmenopausal women ,age range from 2nd to 
8th decade. Incidence in women younger than forty years is only 1-8 %[68]. 
 
CLINICAL FEATURES: 
More than eighty percent of endometrial tumor belong to Type I. Most 
women affected are postmenopausal  but the age range is from second to eighth 
decade. Incidence of endometrial adenocarcinoma in women younger than 40 
years is only 1 to 8 %[69,70]. The  tumor is of low grade with minimal  
invasiveness in young women. 
Most but not all of the patients had menstrual irregularity, obesity,  
infertility and hirsutism.  
Most common manifestation is abnormal vaginal bleeding,in some cases 
it can be asymptomatic[71]. 
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Role of imaging in endometrial carcinoma: 
The common investigation in use is the transvaginal ultrasound[72 ].The 
endometrial thickness of five millimeter  is considered as the upper limit of 
normal. 
Computed tomography or Magnetic resonance imaging  can be done for 
staging  for  preoperative assessment. 
 
WHO  CLASSIFICATION  OF ENDOMETRIAL  CARCINOMA 
[ANNEXURE I]: 
ENDOMETRIOID ADENOCARCINOMA: 
They resemble non neoplastic endometrium in light and electron 
microscopy. 
 GROSS: 
Presents as a exophytic  polypoidal mass or as a diffuse infiltration in to 
the myometrium. Poorly differentiated tumors are manifested by necrosis.  
Endometrial adenocarcinoma usually spreads by direct myometrial 
invasion,then it disseminates  to regional lymph nodes and periuterine 
structures. 
 
  
21 
 
   GRADING: 
Grading is based on microscopic tumor appearance . According to FIGO   
and WHO classification   Endometrioid   adenocarcinomas are divided in to  
three grades based on amount of solid  and glandular  areas and  nuclear atypia. 
Architectural grading is based on the extent of  solid areas when 
compared to  well formed glands. 
Any type of differentiation in endometrioid carcinoma like squamous 
type should not be included in grading system. 
The architectural appearance can differ from one area to another, the 
entire tumor architectural appearance should be taken into account for final  
grading.[TABLE 1&2]. 
TABLE 1 : Architectural grading of Endometrioid adenocarcinoma 
                                      
  
GRADE DIFFERENTIATION % OF SOLID AREAS 
1 Well differentiated Less than five percent 
2 Mod differentiated Six to fifty percent 
3 Poorly differentiated More than fifty percent 
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TABLE 2 : Nuclear grading 
 
            GRADE 1 
 
Nuclei oval,mild enlargement,even 
chromatin. 
 
            GRADE 2 
 
Midway between 1 and 3  grades 
 
            GRADE 3 
 
Enlarged pleomorphic nucleus,coarse 
chromatin with prominent nucleoli. 
 
If nuclear grade is higher than the architectural grade then the overall 
grade is based on nuclear grade. 
The frequencies  of occurence  of grade 1,2,3 Endometrial carcinomas 
are 50 %,35% and 15% respectively. 
Obermair et al stated that  Grading  of endometrioid  carcinoma  
between curettage and hysterectomy has a fifteen  to twenty five percent 
discordance rate[73]. 
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VARIANTS  OF ENDOMETRIOID ADENOCARCINOMA: 
¾ VILLOGLANDULAR CARCINOMA:  
It ‘s architecture is papillary with fibrovascular core that are delicate  
lined by columnar cells with bland nuclei[74,75]..This type is better differentiated 
,but similar to endometrioid adenocarcinoma. 
 Common in postmenopausal age group. The nuclear atypia is usually  
mild to moderate . It has superficial myometrial invasion only. 
Modality of management is similar to endometrioid adenocarcinoma. 
 
¾ SECRETORY CARCINOMA:  
Resembles  secretory endometrium , the uninvolved  endometrium 
shows late secretory pattern. Many  cells  exhibit prominent supra nuclear or 
subnuclear vacuoles. 
Represents less than two percent of endometrial carcinomas,age group  
affected are usually postmenopausal  women  with age ranging from  fifty five 
to fifty eight years[76]. 
The microscopic picture  shows  glands which are well differentiated 
,lined by unstratified  columnar cells with vacuoles in cytoplasm. Grade of the 
nucleus is usually one. 
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Treatment modality is similar to endometrioid adenocarcinoma. It 
carries a favourable prognosis[76]. 
 
¾ CILIATED CARCINOMA: 
It is a rarely occurring low grade endometrioid carcinoma. Commonly 
affected age group is post menopausal women. Estrogen therapy has been 
associated with it. 
In microscopy it is similar to endometrioid carcinoma well differentiated 
type, but the cells have cilia and  eosinophilic  cytoplasm ,nucleoli is prominent 
.Ciliated carcinoma has  a cribriform pattern. 
 
¾ ENDOMETRIOID CARCINOMA - SQUAMOUS 
DIFFERENTIATION: 
The amount of squamous elements should constitute atleast ten percent in 
order to consider it as adenocarcinoma containing squamous differentiation. 
 
Depending on the cytology of squamous elements , these can be categorized  
in to two types  
• Adenoacanthoma 
• Adenosquamous   
But generally these are graded according to the architecture of glandular 
structures similar to endometrioid adenocarcinoma. 
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Microscopically, in adenoacanthoma  benign squamous structures with 
keratin pearls and intercellular bridging  is seen. 
In adenosquamous carcinoma, squamous structures are high grade with 
atypical nuclei. Behavior depends on the grade, with high grade tumors 
demonstrating higher rate of  invasion and metastasis. 
Other types of endometrial carcinoma are, 
 MUCINOUS CARCINOMA:  
It resembles endocervical mucinous carcinoma. To be considered as 
mucinous type the tumor should demonstrate PAS positivity with resistance to 
diastase in atleast fifty percent of tumor cells. They usually exhibit a 
villoglandular architecture lined by columnar cells showing mild stratification. 
If the mucin component is less than fifty percent then the tumor can be 
called  like endometrioid carcinoma with mucinous differentiation. 
Most of them are of low grade exhibiting good prognosis. 
 
 SEROUS CARCINOMA:    
Aggressive tumor, about 90 percent cases associated with EIC. It displays a 
papillary pattern with high nuclear grade. 
Patients are usually in postmenopausal age group. 
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Gross: 
It has a papillary and exophytic appearance.The affected uteri are 
generally small and atrophic. 
Microscopy: 
Cells have high nuclear to cytoplasmic ratio , high mitotic rate, necrosis, 
psammoma bodies, complex papillary architecture which are short and fibrotic,  
some exhibit nuclear hobnailing. It can form tubuloglandular pattern 
mimicking endometrioid carcinoma[77]. 
 
Behavior: 
              It has a tendency for lymphatic and deep myometrial invasion.  So 
careful staging is mandatory because it has a tendency for extrauterine  spread  
even with minimal invasion of   myometrium. 
 
 CLEAR CELL CARCINOMA: 
It is a TYPE 2 carcinoma. It has a mullerian origin[78]. Common affected 
women are in the age group of sixty years.  
 
Microscopically, it’s a high grade tumor containing  pleomorphic cells  with 
nuclear hobnailing and abundant clear cytoplasm in papillary ,tubular and solid 
patterns. 
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It’s a high grade tumor presenting in higher stage. Treatment depends on 
the stage but chemotherapy is given irrespective of tumor stage. 
 
  MALIGNANT MIXED MULLERIAN  TUMOR: 
It also has been included under TYPE 2 carcinoma. 
Occurrence is five percent  of  malignancies in uterine corpus[79].  
Occurs commonly in post menopausal women.  
Risk factors are   
• Obesity 
• Nulliparity 
• Estrogen intake 
• Tamoxifen treatment 
• Irradiation of pelvis 
• P53 mutation 
• PTEN mutation  
• Abnormal  DNA mismatch repair genes. 
 
Clinically the age group of affected women are usually in their seventies 
but it has a wider age ranging from 4th to 10th decade of life. 
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Gross: 
It commonly presents as a polypoidal mass protruding through the 
external os  with vaginal bleeding.The  tumor is often necrotic. 
Microscopy: 
Has a biphasic appearance containing both  carcinomatous  and 
mesenchymal   elements. The  epithelial component can be serous/ 
endometrioid / clear cell/ squamous or mucinous type. 
The stromal component can be either homogenous containing spindle 
cells or it can be heterogenous  with chondrosarcomatous or 
rhabdomyosarcomatous features. 
Histopathogenesis: 
It is  a carcinoma with mesenchymal differentiation ,occurring as a 
result of metaplasia[80]. 
Very aggressive variant. 
 
 UNDIFFERENTIATED CARCINOMA:           
Gross: 
Presents as a necrotic polpoidal mass with frequent involvement of 
lower segment of uterus. 
 
29 
 
Microscopy: 
It exhibits no differentiation. Composed  of sheets of discohesive 
monotonous  cells of small to intermediate morphology  and prominent 
nucleoli  with no obivious  architecture. 
It has an abnormality in DNA mismatch repair genes. It has been grouped 
under TYPE 2 pathogenesis. Has a worst prognosis than a grade 3 
endometrioid carcinoma[81] 
 
 SMALL CELL NEUROENDOCRINE CARCINOMA: 
Its an aggressive tumor .Positive for NSE, cytokeratin and  
synaptophysin. 
 
 SQUAMOUS CELL CARCINOMA: 
Pure squamous carcinoma is rare  endometrium. Extension from cervical 
carcinoma should always be ruled out.  
 
For diagnosing squamous cell carcinoma the following criteria is followed  
• There should be no connection between the squamous epithelium 
of endometrium and cervical squamous epithelium 
• Adenocarcinoma absent in endometrium 
• Cervix does not contain squamous cell carcinoma. 
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 UROTHELIAL CARCINOMA: 
Resembles urothelial carcinoma of urinary tract , but has a mullerian 
profile. 
 
 HEPATOID CARCINOMA:  
Can be associated with increased AFP. 
 
 SIGNET RING CELL ADENOCARCINOMA: 
Possibilities of metastasis should always be ruled out. 
 
IMMUNOHISTOCHEMICAL FEATURES: 
Endometrioid carcinoma are positive for keratin 7,8,18,19. Most are 
positive for cytokeratin 7  and negative for cytokeratin 20[82]. 
Over 80% of cases are positive for vimentin. Coexpression of keratin 
and vimentin is common [83]. 
Estrogen and progesterone receptor positivity in FIGO grade 1,2 is 
higher whereas in grade3 it is seen only in half of the cases[84]. 
In a study by Rolitsky et al Her2 neu overexpression is seen in 20 
percent cases of endometrial adenocarcinoma[85]. 
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Beta catenin and E-cadherin expression is seen in endometrioid 
carcinoma and absent in serous carcinoma[86]. 
IMP3 oncofetal protein is expressed in serous carcinoma not in 
endometrioid carcinoma[87,88].CD117 is expressed in normal endometrium ,also 
in fifty percent of endometrioid adenocarcinoma[88]. 
Overexpression of P53 is present in FIGO  grade 3 adenocarcinoma .It’s 
positive  serous, clear cell and undifferentiated carcinomas[89,90]. 
 
THYROID TRANSCRIPTION FACTOR(TTF 1): 
TTF 1 marker which is associated with thyroid and lung cancer is also 
expressed in endometrial adenocarcinoma[91,92]. 
 Zhang PJ et al stated that TTF 1 can also be positive in extrapulmonary 
adenocarcinoma[93].. In endometrioid carcinoma ,grade 3 adenocarcinomas 
showed  diffuse positivity for TTF 1.Deavers et al studied that there was no 
correlation between TTF 1 positivity and tumor differentiation[94]. 
In a study by Zhang et al TTF 1 positivity is about 80% in MMMT [93]. 
Thyroid transcription factor  expression has also been noted in 
nonneoplastic endometrium,fallopian tube ,endocervix[7]..  
TTF 1 expression  low grade  endometrial carcinomas has a poor 
outcome[6]. 
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Ervine et al[6] showed that  TTF 1 expression ; TABLE 3 
 
Low grade endometrial carcinoma 
 
Two percent of cases 
 
Grade 3 carcinoma 
 
Eleven percent of cases 
 
Clear cell carcinoma 
 
Seven percent of cases cases 
 
Serous carcinoma 
 
Nine percent of  cases 
 
Napsin A and TTF 1 are used for separation of primary lung carcinoma 
from metastatic  carcinoma  like endometrial carcinoma[95]. 
In a study by jaudah et al ,most endometrial carcinomas are TTF 1 
negative. The positive cases expressed only weak positivity and diffuse 
positivity is not seen  in them[7]. 
For an unknown primary with focal  TTF 1 positivity,differential 
diagnosis of endometrial adenocarcinoma  should be considered. 
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TNM/FIGO (2009) staging (ANNEXURE II): 
Changes made in new FIGO(2009)  contribution from ISOGP are 
9 Carcinomas without invasion in to  myometrium  and tumors with less 
than 50 percent invasion of  myometrium  in STAGE IA. 
9 Gland invasion in cervix is eliminated in STAGE II 
9 Positive cytology  in peritoneal fluid  excluded  from STAGE IIIA 
9 Pelvic , paraaortic  nodes metastasis is separated in stage IIIC. 
For complete staging Total abdominal hysterectomy  with bilateral 
salpingo – oophrectomy  along with pelvic and paraaortic node assessment is 
needed[96]. 
When myometrial invasion is  50%  or  poorly differentiated 
endometrioid carcinoma with myometrial invasion,  adjuvant radiotherapy is 
given in addition to surgery. 
 
TUMOR  SPREAD  AND  METASTASIS: 
Most important  route of spread  is by lymphovascular invasion. 
Pelvic,paraaortic nodes and ovaries are the most common sites of extrauterine 
spread of endometrial adenocarcinoma. 
Lymph node metastasis occurs in five to twenty five percent of stage I  
carcinomas and it is most likely present in  high grade invasive tumors[97]. 
Vaginal vault and pelvis are the most sites for tumor recurrence. 
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Distant metastasis  occurs in lungs, CNS,  skin  ,liver  and bone. 
TREATMENT: 
Hysterectomy with bilateral salpingo-oophrectomy is the standard 
treatment modality. Chemotherapy and radiotherapy can be given either 
preoperatively or postoperatively. 
Usually patients are administered postoperative radiotherapy ,if they 
have poor prognostic conditions. 
Patients can be categorized into two groups  
• Low  risk group -  tumors of grade one/two limited to endometrium / has 
minimal myometrial invasion. Does not require postoperative 
radiotherapy. 
• Intermediate risk group – patients included are those that do not qualify 
into low/ high risk groups. 
• High risk group -  patients with adnexal involvement, nodal metastasis 
.Thes patiemts require postoperative radiotherapy. 
 
Recurrent tumors are treated with hormone,  radiation and cytotoxic therapy. 
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PROGNOSTIC FACTORS: 
¾ AGE: 
Young women mostly have low grade tumors. One study suggests 
decreased life span for women more than 50 years of age[98]. 
¾ GRADE: 
Prognosis for high grade tumors is poor   regardless of their histologic 
type[99].. Women having low grade endometrial carcinoma limited to inner 
half of myometrium have a five year survival rate of hundred percent, 
where as patients with low grade tumor morphology  but presenting  at a 
higher stage  have a five year survival rate of sixty seven percent. similarly 
high grade tumors at advanced stages have only twenty six percent five year 
survival rate[100]. 
¾ MYOMETRAL INVASION: 
It is an important factor in prognosis.The depth of invasion is related to 
number of  nodal metastasis, incidence of pelvic node metastasis rises to 
twenty five percent  in tumors showing  greater than fifty percent 
myometrial invasion. 
¾ INVOLVEMENT OF CERVIX: 
Tumors without extrauterine involvement  but with cervical invasion is  
associated with an increased risk of  recurrence rate of about sixteen percent 
[101]. 
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¾ STAGE : 
It helps to plan the treatment method. Myometrial invasion  greater than 
50 percent is associated with worst prognosis[102]. 
¾ TUMOR TYPE: 
Clear cell carcinoma, Papillary serous carcinoma, MMMT  tumors are 
highly aggressive than the high grade variants of endometrioid 
carcinoma[103,104]. 
¾ LYMPHOVASCULAR INVASION:  
It’s a poor prognostic factor [105]. 
¾ PERITONEAL WASH:  
Positivity of tumor cells in the peritoneal fluid  is an  independent  
determinant of increased recurrence and decreased survival[106]. 
¾ PLOIDY: 
Aneuploid tumors are  high  grade tumors and  has worst prognosis[107]. 
¾ ANGIOGENESIS: 
Increased vascularity is associated with decreased survival[108]. 
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MATERIALS AND METHODS 
This study is a prospective and  retrospective  study of endometrial  
cancer in hysterectomy specimens conducted in the Institute of pathology  at 
Institute of obstetrics and gynaecology ,Madras Medical College and Rajiv 
Gandhi Government General Hospital,Chennai during the period between 
January  2010 to December  2014.  
A total of 17,032  cases were submitted to our Institute  of  pathology, at   
Institute of obstetrics and gynaecology Madras medical college during the 
period of January  2010 to December  2014 for histopathological examination. 
Out of them 93 cases of endometrial  carcinoma  in hysterectomy specimens 
were  reported. 
 
Inclusion criteria: 
Patients diagnosed as Endometrial adenocarcinoma - conventional type 
& its variants, Malignant mixed mullerian tumor of uterus. 
 
Exclusion criteria: 
Benign tumors and non epithelial tumors of uterus. Cases for which only 
fractional curettage was done. 
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METHOD OF DATA COLLECTION: 
Detailed history of the cases regarding age, menstrual status, clinical  
history, parity, fractional curettage and staging laparatomy were obtained for 
all the 93 endometrial carcinoma  cases reported during the period of study 
from surgical pathology records. Hematoxylin and Eosin stained 4 µ thick 
sections of the paraffin tissue blocks of specimens were reviewed. The 
following clinical and pathological parameters were evaluated: Age, parity, 
menstrual status, tumour type, tumour grade, stage.  
Endometrioid carcinoma was classified as well differentiated, 
moderately differentiated, poorly differentiated based on differentiation. 
Among 93 cases  endometrial carcinoma  53 cases were well differentiated 
endometrioid adenocarcinoma  including one villoglandular variant,15 cases 
were moderately differentiated endometrioid carcinoma , 16 cases were poorly 
differentiated endometrioid  carcinoma , 1 case of serous carcinoma, 3 cases  
clear cell carcinoma , 4 cases  malignant mixed mullerian tumour and 1 case of 
undifferentiated carcinoma. 
Among 93 cases, 50 cases were randomly selected and their 
representative formalin fixed and  paraffin embedded tissue samples was 
subjected  for  TTF 1 immunohistochemistry.  
                        
 
39 
 
IMMUNOHISTOCHEMICAL EVALUATION: 
Immuohistochemical analysis of marker TTF 1 was  done in paraffin 
embedded tissue samples using Super-sensitive polymer HRP system based on 
non-biotin polymeric technology.[TABLE 4]. 4 µ thick sections from formalin 
fixed and paraffin embedded tissue samples was transferred onto gelatin coated 
slides. Heat induced antigen retrieval was done. The antigen was bound with 
rabbit monoclonal antibody (Pathnsitu) against TTF 1  protein  and then 
detected by adding  secondary antibody conjugated  horse radish peroxidase-
polymer and diaminobenzidine substrate.  Step by step procedure of 
Immunohistochemistry is given in Annexure III. 
                                      TABLE 4: TTF 1 MARKER 
 
Antigen 
 
Vendor 
 
Species(clone)
 
Dilution 
 
Positive 
control 
 
TTF 1 
 
PATHNSITU 
 
Rabbit 
 
Ready to use 
 
Thyroid 
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INTERPRETATION AND SCORING SYSTEM: 
The immunohistochemically stained slides were analyzed for the 
presence of reaction, nuclear localization, percentage of cells stained  
and intensity of reaction.  
 
SCORING OF TTF 1: 
TTF 1 nuclear staining was scored based on scoring done by W Glen 
McCluggage[6]. 
1) Negative ( absent ) 
2) Focal (< 50 % nuclear staining) 
3) Diffuse (>50% nuclear staining) 
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STATISTICAL ANALYSIS: 
• Immunohistochemical analysis was done in paraffin embedded tissue 
samples using the statistical package for  social science software version 
IBM SPSS version 20 which consisted computing the frequency counts 
and percentages for qualitative variables and mean for quantitative 
variables. 
• The correlation between TTF1 expression and various parameters was 
calculated using pearson chi square test.  
• P value 0.05 was considered as a cut-off point for  determination  of 
statistically significant results. 
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OBSERVATION AND RESULTS 
In the study period of 5 years from January 2010 to December 2014,a 
total  of  17032 specimens were received in the Institute of obstetrics and 
gynaecology, Madras Medical College for histopathological examination. Total  
number  of  endometrial carcinoma in hysterectomy specimens were 93 cases 
during this five year period.  
 
TABLE 5 : HISTOLOGICAL TYPES OF ENDOMETRIAL 
CARCINOMA 
Histological types Number of cases Percentage 
Welldifferentiated 
endometrioid carcinoma 
52 55.9% 
Moderately differentiated  
endometrioid carcinoma 
15 16.1% 
Poorlydifferentiated 
endometrioid carcinoma 
16 17.2% 
MMMT 4 4.3% 
Clear cell carcinoma 3 3.2% 
Villoglandular carcinoma 1 1.1% 
Serous carcinoma  1 1.1% 
Undifferentiated ca 1 1.1% 
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In this study about 32 cases are reported in  age group fifty one to sixty 
years years. The youngest age and oldest age at which endometrial carcinoma 
was diagnosed in this study is 27 years and 78 years. 
Age group and  histological types of endometrial carcinoma:                                        
 
 
 
TABLE 7:AGE GROUP AND HISTOLOGICAL TYPE 
 
Age group 
Histological type 
Total
Clear ca MMMT 
Mod 
diff 
Poor 
dif 
Serous 
ca 
Undif 
ca 
VG ca 
Well 
dif 
 20-30 Yrs 0 0 1 0 0 0 0 0 1 
31-40 Yrs 
 
0 0 2 2 0 0 0 3 7 
41-50Yrs 
 
1 1 4 6 0 0 0 16 28 
51-60Yrs 
 
0 2 3 5 1 1 1 19 32 
> 60   Yrs 
 
2 1 5 3 0 0 0 14 25 
Total 3 4 15 16 1 1 1 52 93 
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               CHART  3 : AGE GROUP AND HISTOLOGICAL TYPE
 
On assessing age incidence of different  types of endometrial carcinoma,  
1 case   moderately differentiated endometrial carcinoma has been reported in 
the age group 20 – 30 years.[TABLE7 & CHART 3]. 
Maximum of 32 cases were diagnosed in the age group  51 – 60 years. 
Out of  them 19 were well differentiated endometrioid carcinoma,5 cases of 
grade 3 endometrioid  carcinoma,3 cases  of  grade 2 endometrioid  
carcinoma,2 cases   malignant mixed mullerian tumour and 1 case each  in 
serous, undifferentiated and villoglandular carcinomas . 
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About 2 cases of clear cell carcinoma ,5 cases of moderately 
differentiated, 3 cases of poorly differentiated  and 14 cases of  well 
differentiated  endometrioid carcinoma were diagnosed  in women  above 60 
years. 
 
Menstrual  status: 
                                      TABLE 8 : MENSTRUAL STATUS 
 
Menstrual  status 
 
Number of cases 
 
Percentage 
 
Premenopausal 
 
8 
 
8.6% 
 
Perimenopausal 
 
35 
 
37.6% 
 
Postmenopausal 
 
50 
 
53.8% 
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Women  are grouped in to 3 categories , women aged  less than 40 years  
are categorized in the premenopausal  age group, women aged  within 40 to 55 
years and  women  over 55 years  are included in  perimenopausal and  
postmenopausal  category.[TABLE 8&CHART 4]. 
In this study, out of the 93 cases  maximum  of 50 cases were reported  
with a percentage of  53.8% in the  postmenopausal age group. In 
perimenopausal women 35 cases  and  8 cases in premenopausal women. 
 
9%
38%53%
CHART 4:MENSTRUAL STATUS
premenopausal
perimenopausal
postmenopausal
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Parity : 
            TABLE 9 : PARITY AND ENDOMETRIAL CARCINOMA 
Parity Number of cases Percentage 
Parous 77 82.8% 
Nulliparous 16 17.2% 
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In this study majority of  women  with endometrial carcinoma  are 
parous  having a frequency of 77 cases with a percentage of 82.8 %  and  17.2 
% women are nulliparous.[TABLE 9&CHART 5]. 
 
Clinical features : [TABLE 10 &CHART 6] 
                         TABLE 10 : CLINICAL FEATURES 
Symptoms Percentage 
Post menopausal bleeding 54% 
Bleeding pv 45% 
Abdominal pain 11% 
White discharge 4% 
Mass descending per vagina 1% 
 
 
51 
 
 
  
In this study majority of women about 54% presented with 
postmenopausal bleeding. About 45 % women had irregular bleeding per 
vagina, 11%  presented with abdominal pain, 4 %  with white discharge and 1 
% with mass descending per vagina. 
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 During this 5 year study, the majority of cases  were well differentiated 
endometrioid carcinoma  accounting for  55.9% of total cases. 
 
Grade of endometrioid carcinoma: [TABLE12&CHART 8]. 
TABLE 12:  Different grades of endometrioid carcinoma 
 
Grade 
 
Number of cases 
 
Percentage 
 
1 
 
53 
 
57% 
 
2 
 
15 
 
16.1% 
 
3 
 
16 
 
17.2% 
 
 
 
54 
 
 
 
The incidence  of  different grades of endometrioid carcinoma  in the 5 
year period from January 2010 to December 2014  were  57 %  for grade 1 
endometrioid carcinoma including  villoglandular carcinoma, 16.1% for grade 
2 endometrioid carcinoma and 17.2%  for grade 3 endometrioid  carcinoma. 
Among  different grades  of endometrial carcinoma  well differentiated  grade  
has the  commonest  occurrence in this 5 year study. 
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Type of   endometrial  carcinoma: 
                              TABLE 13: Type  of endometrial carcinoma 
 
Type 
 
Number of cases 
 
Percentage 
 
1 
 
68 
 
73.1% 
 
2 
 
25 
 
26.9% 
 
 
In this study incidence of  Type  1 carcinoma is 73% and  Type 2  
carcinoma is 27%.[TABLE13&CHART 9]. 
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Comparison  between TYPE  of endometrial carcinoma and  Age group 
:[TABLE 14&CHART10] 
TABLE 14 : TYPE  and age group 
Age group Type 1 Type 2 Total 
20-30 yrs 1 0 1 
31-40yrs 5 2 7 
41-50yrs 20 8 28 
51-60 yrs 23 9 32 
Above 60 yrs 19 6 25 
 
               
 
 C
Mo
60 years in
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
HART 1
st of type I
 this study
20-30 Yrs
100%
0
0:  Compa
 and type 
. 
31-40 Yrs
71%
%
29
57
rison bet
2  carcinom
41-50 Yrs
71%
% 29%
TYPE 1
ween TYP
a occurre
51-60 Yrs
72%
28%
TYPE 2
E and age
d  in the ag
Above 60 
Yrs
76%
24
 group
e group o
TYPE 1
TYP
%
 
f 51 to 
E 2
58 
 
FIGO Stage: 
TABLE 15: FIGO STAGING OF ENDOMETRIAL CARCINOMA 
Stage Number of cases Percentage 
IA 43 46.2% 
IB 25 26.9% 
II 11 11.8% 
IIIA 7 7.5% 
IIIB 1 1.1% 
IIIC1 2 2.2% 
IIIC2 2 2.2% 
IVA - - 
IVB 1 1.1% 
Not done 1 1.1% 
 
Majority of cases  of endometrial carcinoma in this 5 year  study  
presented  in stage IA  with a percentage of 46.2%, 25 cases presented in stage 
IB ,11 cases in stage II,7 cases in  stage IIIA, 1 case in stage IIIB,2 cases each 
in stage IIIC1 and IIIC2,1 case in stage in stage IVB.In one case  the specimen 
was received  in piecemeal  so staging was not done. 
[TABLE15&CHART11]. 
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TTF 1  expression  and  grade of endometrial carcinoma: 
TABLE 17:TTF1 expression with grade  
TTF 1 expression GRADE Total 
1 2 3 
TTF1 
diffuse 
Count 0 0 1 1
%  
 0.0% 0.0% 14.3% 2.2%
Focal 
Count 0 2 0 2
%  
 0.0% 25.0% 0.0% 4.4%
Neg 
Count 30 6 6 42
%  
 100.0% 75.0% 85.7% 93.3%
            Total 
Count 30 8 7 45
%  100.0% 100.0% 100.0% 100.0%
p=0.004* 
                             
In this  study  for 30 cases of  well differentiated endometrioid 
carcinoma (Grade 1),8 cases of Grade 2,7 cases of  Grade 3 endometrioid 
carcinoma, 2  clear cell carcinoma and  3  MMMT  ,TTF1 marker was done. 
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TTF 1 and TYPE of  endometrial carcinoma: 
                   TABLE 18: TTF 1 and TYPE of endometrial carcinoma 
 
TTF1 
 
TYPE 1 
 
TYPE 2 
 
Diffuse 
 
0 
 
1 
 
Focal 
 
2 
 
0 
 
Negative 
 
36 
 
11 
 
On studying  the expression of TTF 1 in relation to type of endometrial 
carcinoma, out of 12 cases in type2,a diffuse positivity was  noted in one case 
of type 2 – poorly differentiated endometrioid carcinoma.In type 1 carcinoma 
out of 38 cases,  focal positivity was observed in 2 cases of moderately 
differentiated endometrioid carcinoma.[TABLE 18&CHART14] 
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The  TTF 1 positive cases fall under the peri menopausal and post 
menopausal age group. 
TTF 1 expression with stage of endometrial carcinoma: 
TTF 1  and stage of endometrial  cancer is studied.                       
                                             
                                           
 
 
                                   TABLE 21: TTF 1 and stage 
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DISCUSSION 
Endometrial carcinoma  is the common gynecological  malignancy next 
to cervical  and ovarian carcinoma. 
This study is a prospective and  retrospective study from January 2010 
to December 2014 on endometrial carcinoma in the Institute of obstetrics and  
gynecology  , madras medical college. A total  of 93 cases were received in the 
hysterectomy specimens. Out of the 93 cases , well differentiated endometrioid 
carcinoma  were 52,moderately differentiated endometrioid carcinoma were 15, 
poorly differentiated  endometrioid carcinoma were 16 cases, serous carcinoma 
1 case, clear cell carcinoma 3 cases, villoglandular carcinoma 1 case, 
undifferentiated carcinoma 1 case, MMMT  4cases. 
 
Incidence : 
Endometrioid  carcinoma  represents  about 90%  of  the  total  cases  in 
this study. This is in accordance  with the study done by Nirmala et al [109] ,  in 
which  endometrioid type constitutes 75 – 80 %. 
Serous carcinoma  incidence  during  these 5 years  in this study  is 1%, 
in literature its incidence is about  5 - 10 % and clear cell carcinoma incidence 
is  3%, in accordance with study done by Nirmala et al[109],  where the 
incidence was between 3-5%. 
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MMMT incidence in this study  is 4 % .According  Silverberg et al [77], it’s 
incidence is 5%. 
 
Age group: 
The age group affected most frequently in this study is 51 – 60 years 
with a age range of  20 to 80 years. Mean  age  is 54 years .Incidence  of 
endometrial carcinoma in women aged below 40 years  is 8.6% , in a study 
done  by  Ota T et al  [110] where the incidence is between 2 to 14%. 
The youngest age affected is 27 years  in this study . In a study by Farhi 
DC et al[111] , the youngest age of women  with endometrial carcinoma is 15 
years. 
 
Age group and histological type of endometrial carcinoma: 
In  this study ,  in women aged below 40 years ,most of them  have  low 
grade endometrioid carcinoma  about 6.4% . In a study  by  Garg K et al[112] 
states that in women below 40 years low grade  endometrioid carcinoma is 
common. 
High grade endometrioid carcinomas, clear cell carcinoma ,serous 
carcinoma and MMMT  occur in women above 40 years. This is similar to the 
71 
 
study done by Hafezi S et al[113], which states that elderly women have more 
incidence of high grade endometrial carcinoma. 
 
Menstrual status: 
In this 5 year study  93 cases of endometrial carcinoma , incidence in 
premenopausal women  is 8.6 %, perimenopausal women is 37.6%, post 
menopausal women is  53.8%.So, the highest incidence rate is in 
postmenopausal  women, this is in accordance to various studies in 
literature[114,115]. Soliman et al  stated  that endometrial carcinoma  has  mean 
age incidence  of 61 years ,commonly in post menopausal women[116]. 
 
Parity: 
In this study , most of the women with endometrial carcinoma are 
parous accounting for 82.8%, whereas nulliparous  women has an incidence of  
17.2%. 
The  literature  states that nulliparous women have increased incidence 
of endometrial carcinoma.  According to Soliman et al[116]  incidence rate in 
nulliparous women  was 54%.But  in this study most were parous women. 
 
Clinical features: 
In  this study 54%  patients presented with  postmenopausal  bleeding 
,45% with irregular bleeding pv,abdominal pain 11%,white discharge 4%,mass 
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descending  pv 1 %.According ESMO guidelines 2013[1] the most common 
presenting symptoms  is abnormal  uterine bleeding  accounting for more than 
90% . 
 
Gross: 
In the 50 randomly selected cases  the gross features were assessed, 
more than 90%  have proliferative growth. Literature also states that most have 
exophytic  appearance[117]. 
 
Histological types: 
Conventional   endometrioid  adenocarcinoma  constitutes about 90% in 
this study, with  grade 1 carcinoma constituting about 63%, grade 2  constitutes 
18% and grade 3 constitutes 19% . Literature  states  that about 50 % are well 
differentiated, 35 %  are moderately differentiated and 15% poorly 
differentiated[112]..But in this study moderately differentiated  endometrioid 
carcinoma  has a 1% higher incidence than poorly differentiated carcinoma. 
The occurrence of  clear cell carcinoma in this study is 3.2 %, in 
accordance to the study done by Joyce varughese et al  [119]where the 
incidence is between 1%  to  6%.  
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Abler et al [120] stated that the incidence of uterine serous carcinoma is 
1%, in this study also only one case was reported accounting for 1.1% 
 In a study by Silverberg et al [121] the incidence of  MMMT  is around 
5%, in this 5 year  study  also the incidence is about 4.3%. 
 
Type of endometrial carcinoma: 
The incidence of type 1 carcinoma  during  this 5 year period 2010 to 
2014, is 73% and type 2 carcinoma is 27%.According to  Liu FS et al [122], 
incidence of type 1 carcinoma  is 70 to 80% and type 2 carcinoma  is  between 
10 % to 20%.Thus the incidence stated in this study correlates with the 
literature studies. 
 
FIGO staging: 
Out  of the 68 cases  in stage I  about 45 cases  of well differentiated 
carcinoma  accounting for 66% was reported ,moderately differentiated   
endometrioid carcinoma  was 13%,poorly differentiated endometrioid 
carcinoma was 11%,MMMT  was  4% , clear cell carcinoma was 1%.Thus 
majority of cases in stage I  are  low grade endometrioid carcinoma . F.K.L 
Tournois et al[132]  in his study  also  has mentioned that most of  women with 
endometrial carcinoma  about 78.5%  were diagnosed in stage  I and most of 
them  were grade 1 endometrioid  carcinoma 41.3%, moderately differentiated 
endometrioid carcinoma  38%,poorly differentiated endometrioid carcinoma 
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20.7%.Thus in stage I most cases  were well differentiated endometrioid 
carcinoma. 
In stage II  about 11 cases accounting for  11.8% of total  cases  were 
reported, majority were poorly differentiated  endometrioid  carcinoma  6 
cases, 2 cases  well differentiated carcinoma , 1 case each from clear cell 
carcinoma  and MMMT . F.K.L Tournois et al [123] in his study  reported  
5.2% cases in stage II. 
In stage III total of 12 cases were reported accounting for 13%.One case 
of undifferentiated carcinoma presented in stage IIIB. F.K.L Tournois et al[123]  
in his study reported  about 11%  cases  in stage III. He has  stated that  
incidence of grade 3 endometrioid carcinoma  in stage III  is higher but in this 
study no such association is found.  
In stage IV B only one case  (1.1%) of moderately differentiated 
endometrioid  carcinoma was  reported . F.K.L Tournois et al [123] reported  
2.5% in stage IV. 
TTF 1 expression in endometrial carcinoma: 
In   this study for 50 random cases including   30 cases of well 
differentiated endometrioid adenocarcinoma, none of them expressed positivity 
for TTF 1. 
 Out of the 8 cases of Moderately differentiated endometrioid carcinoma   
2 cases showed  focal positivity accounting for 25% and 75% were negative. 
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In a study by Aaron ervine et al [6]for 100 cases of low grade endometrioid 
carcinoma only 2 cases showed positivity  ,one case showing diffuse positivity, 
other one showing focal positivity and  98% cases were negative. 
In this study out of 38 cases, 2 cases of low grade endometrioid 
adenocarcinoma  showed focal positivity  for TTF 1 accounting for 5%. This is  
in concurrence with the study by Aaron ervine et al [6]. 
Out of  7 cases of poorly differentiated endometrioid carcinoma  only 
one case showed diffuse positivity accounting for 14%.This is in concurrence 
with the study done by Aaron et al [6], where out of total 101 cases, 89% cases 
are negative, 7%  cases are diffusely positive, 4%  are focally positive. 
In this study TTF 1  expression  in clear cell carcinoma , out of  2 cases 
both are negative. This is in concurrence with the study by Jaudah Al- 
Maghrabi et al [7],where TTF 1  was  negative for 2 cases  for which the 
marker was done. But in another study  Aaron et al , TTF 1 positivity was 
found in 2 cases  out of 29 cases  accounting for 7% . 
For 3 cases of  MMMT  ,all were negative  for TTF 1.But according to 
Zhang et al [124], TTF 1 expression  present in 82% cases of MMMT. 
 
TTF 1 and grade: 
In this  study expression  of TTF 1 according to grade was studied. Out 
of  45 cases of endometrioid carcinoma,  2 cases  of  moderately endometrioid 
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carcinoma are positive and one case of  poorly differentiated  endometrioid 
carcinoma. 
In  study by Ervine et al [6]  TTF 1 positivity of  2%  in low grade 
endometrioid carcinoma   and 11% in grade 3 endometrioid carcinoma. 
But in this study only 2% showed  diffuse TTF 1positivity and  4%  
showing  focal TTF 1 positivity. 
Deavers et al [125]  showed that  in a total of 32 cases  of endometrioid 
carcinoma only 5 cases showed  TTF 1 positivity accounting for  16%. 
In this study  out of 45 cases of endometrioid carcinoma, 3 cases showed 
positivity for TTF 1  accounting for 7 %. 
 The  relationship between TTF 1 expression  and grade of endometrioid 
carcinoma has a p value = 0.004,  indicating that relationship is statistically  
significant in this study. Thus TTF 1 expression correlates with the grade of 
endometrioid carcinoma. 
 
TTF 1 and  Type of endometrial carcinoma: 
In 50 randomly  selected cases , 36 cases of type 1 , 2 cases showed 
focal positivity  for TTF 1 with a percentage of 5.5%  and in 11 cases of type 2 
, one case was diffusely positive for  TTF 1 with a percentage of  9%.   On 
statistical assessment  this association was not significant p value > 0.05. 
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TTF 1 and menstrual status: 
In the 50 randomly selected cases, total of 6 cases in premenopausal  
women  all were negative for TTF 1. In perimenopausal women  total of  19 
cases , one case of poorly differentiated  showed diffuse positivity. In 
postmenopausal women  total of 25 cases ,2 cases  of moderately differentiated 
endometrioid carcinoma were focally positive for TTF1. 
For a total  8 cases of moderately differentiated endometrioid 
carcinoma, 3 cases in premenopausal age group,2 cases in perimenopausal age 
group, 2 cases in postmenopausal age group. Two cases were focally positive 
for TTF 1  in the postmenopausal  women whereas it was negative in other 2  
menstrual statuses. 
In poorly differentiated endometrioid  carcinoma only one case out of 
the 7 cases  was positive. It was positive in perimenopausal women. 
Thus the association of  TTF 1 positivity with the menstrual status of  
women in this study  is that  positivity in moderately differentiated 
endometrioid carcinoma occurs in postmenopausal women. 
On statistical analysis  p value = 0.453, showing that association of TTF 
1 positivity with menstrual status of women is not statistically significant. 
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TTF 1  and stage: 
In  this study  out of the three positive cases  for TTF 1 ,for one case  
staging was done as the specimen was received  in fragments  and  the other  
two low grade endometrioid carcinoma ,one case was in stage IA  and other 
was in stage IB. Aaron ervine et al [6] in his study also reported  2 positive 
cases in low grade endometrioid carcinoma in the stage mentioned above. 
In the 5 year study  of  endometrioid carcinoma, 3 cases ( 2-MMMT,1- 
clear cell carcinoma with a percentage of  67% MMMT ,33%  clear cell 
carcinoma) had carcinoma breast .For one case of  MMMT  the women was a 
known case of carcinoma breast diagnosed  before 8 years and for other 2 cases 
carcinoma breast  was diagnosed   synchronously along with carcinoma 
endometrium .  
 But Ashley Sinclair et al [126] in their study reported  carcinoma breast 
in 16% MMMT  and 14% in clear cell carcinoma. 
For the 50 randomly selected cases , follow up details were collected , 
12 cases  follow up details were not available. All the other cases  were treated 
according to their stage of presentation by surgery , chemotherapy and  
radiotherapy. Cases were followed up for a mean duration of  14 months . In 
cases that were positive for TTF 1 , 2 cases  lost follow up  and one case of low 
grade grade endometrioid carcinoma  in stage IB   postsurgery ,  radiotherapy  
was  given  and  she is followed for 7 months  and  there is no adverse 
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behaviour  till now when compared  to other  low grade endometrioid 
carcinoma that were negative for TTF 1. 
According to the study done by Aaron et al [6],TTF 1 positivity in  low 
grade endometrioid carcinoma  is associated with poor prognosis but in this 
study out of the 2 positive cases of low grade endometrioid carcinoma ,follow 
up could not be traced for one and  other case was  followed for 7 months  and 
no difference in survival  was  noted , so comment on the prognosis can be 
made only on long term follow up. 
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SUMMARY 
Among 17032  biopsies  that  were received in the Institute of obstetrics 
and gynecology ,Madras medical college 93 cases of endometrial carcinoma 
were reported  during the 5 year period from January 2010 to December 2014. 
In  93 cases  52 cases (55.9%) were well differentiated endometrioid 
carcinoma, 15 cases (16%)  were moderately carcinoma,16 cases(17%) were 
poorly differentiated carcinoma, 1 case (1%) of  villoglandular carcinoma,1 
case (1%) of serous carcinoma,3 cases(3.2%) of  clear cell carcinoma,4 cases 
(4.3%) of MMMT , 1 case (1%)  of undifferentiated carcinoma .Thus  in our 
study the incidence of  well differentiated  endometrioid carcinoma  is higher 
than other histological types. 
The peak age group incidence of endometrial carcinoma  in our study is 
51 to 60 years accounting for 34.4% where as incidence in women  below 30 
years is 1.1% and incidence in women above 60 years is 27%. 
Most of the endometrial carcinoma in women below 40 years  in our 
study were low grade with a percentage of  6.4%. 
High grade endometrioid carcinoma,clear cell carcinoma,serous 
carcinoma and MMMT  occurred in women above 40 years in this study. 
Incidence of endometrial carcinoma in postmenopausal women is 53.8% 
in our study. 
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The percentage of endometrial carcinoma in   parous  women  is 83% 
and in nulliparus women is 17%. 
In our study the incidence of Type 1 carcinoma is 73% and Type 2 
carcinoma is 27% .Most of the low grade carcinoma presented in stage I in this 
study. 
Among  50  randomly selected cases  TTF 1 marker was done ,only 3 
cases showed positivity for TTF 1. Two cases of  moderately differentiated 
endometrioid carcinoma were focally positive and one case of  poorly 
differentiated carcinoma was diffusely positive for TTF 1 ,all others were 
negative. 
The relationship between TTF 1 positivity and grade of endometrioid 
carcinoma has a p value of 0.004 which is statistically significant. 
On correlating TTF 1 positivity with stage, out of 3 positive cases 2 
cases were in stage IA and IB ,for the other positive case staging was not done. 
 
 
                                        
 
 
                                          
  
 
CONCLUSION 
  
82 
 
 
 
CONCLUSION 
In our study the incidence of different types of endometrial carcinoma  
in the 5 years from January 2010 to December 2014  was studied. 
The aim of our study was to study the expression of TTF 1in 
endometrial carcinoma and also to study  its positivity according  to grade of 
endometrial carcinoma. 
In this study,  total  of  3 cases  of  endometrial carcinoma was positive 
and the relationship between TTF 1 positivity with grade of endometrial 
carcinoma was significant though  majority  of cases of  endometrial carcinoma 
were negative for TTF 1. 
Thus this study confirms that TTF 1 positivity correlates with grade of 
endometrial carcinoma. Out of the 3 positive cases ,the follow up for 7 months  
was available for only  case of  stage I low grade endometrioid carcinoma  and  
the comment on prognosis can only be made on long term follow up. 
 
 
                                                ANNEXURE I 
WHO histological classification of tumours of the uterine corpus 
Epithelial tumours and related lesions 
Endometrial carcinoma                                Tamoxifen related lesions 
 Endometrioid adenocarcinoma                       Mesenchymal tumours 
     Variant with squamous differentiation        Endometrial stromal tumours 
     Villoglandular variant                                     Endometrial stromal sarcoma 
      Secretory variant                                            Endometrial stromal nodule 
      Ciliated cell variant                                        Undifferentiated sarcoma   
Mucinous adenocarcinoma                               Smooth muscle tumours 
Serous adenocarcinoma                                        Leiomyosarcoma 
Clear cell adenocarcinoma                                            Epithelioid variant 
Mixed cell adenocarcinoma                                          Myxoid variant 
Squamous cell carcinoma                                      Smooth muscle tumour of  
Transitional cell carcinoma                                    uncertain malignant potential                            
Small cell carcinoma                                             Leiomyoma, NOS 
Undifferentiated carcinoma                                       Mitotically active  
Others                                                                        Cellular variant 
Endometrial hyperplasia                                         Hemorrhagic cellular 
Nonatypical hyperplasia                                             Epithelioid variant 
                      Simple                                                  Myxoid 
                      Complex                                               Atypical variant 
Atypical hyperplasia                                                   Lipoleiomyoma  
                       Simple                                                  Diffuse leiomyomatosis 
                       Complex                                               Dissecting leiomyoma 
Endometrial polyp                                                       Intravenous leiomyoma 
   Metastasizing leiomyoma                           Tumors of germ cell type 
Miscellaneous mesenchymal tumours           Melanotic paraganglioma 
Mixed endometrial stromal and                     Lymphoid & haematopoeitic 
                     smooth muscle tumour               Malignant lymphoma 
Perivascular epithelioid cell tumour                Leukaemia            
Adenomatoid tumour                                     Secondary tumours 
Other malignant mesenchymal tumours 
Other benign mesenchymal tumours 
Mixed epithelial and mesenchymal tumours 
Carcinosarcoma 
Adenosarcoma 
Carcinofibroma  
Adenofibroma  
Adenomyoma  
Gestational trophoblastic disease 
Trophoblastic neoplasms 
     Choriocarcinoma 
     Placental site trophoblastic tumour 
     Epithelioid trophoblastic tumour 
Molar pregnancies 
Non neoplastic,non molar trophoblastic lesions 
     Placental site nodule and plaque 
     Exaggerated placental site 
Miscellaneous tumours 
Sex cord like tumours 
Neuroectodermal tumours 
                                        
                                                ANNEXURE  II 
FIGO STAGING (2009): 
 IA Tumor  limited  to  the  inner  half  of   myometrium 
IB Tumor  invasion  into the outer half of  myometrium 
II Tumor invades  cervical stroma 
IIIA Tumor invades serosa and/or adnexa 
IIIB Vaginal and/or  parametrial involvement 
IIIC1 Metastases to pelvic lymph nodes 
IIIC2 Metastases to paraaortic lymph nodes 
IVA Tumor invasion of  bladder and/or bowel mucosa 
IVB 
Distant metastases including intraabdominal and/or inguinal 
lymph nodes 
 
                                             ANNEXURE III 
 
Immunohistochemistry procedure: 
Slide Preparation: 
1. Sections with a thickness of 4 µ were cut from formalin fixed paraffin 
embedded tissue samples and transferred to gelatin-chrome alum coated 
slides. 
2. The slides were incubated for overnight at 58ºC. 
3. The sections were  deparaffinised in xylene for 15 minutes x 2 changes. 
4. The sections were dehydrated with absolute alcohol for 5 minutes for 2 
changes. 
5. Then the sections were  washed with  tap water for 10 minutes. 
6. The slides are  then immersed in distilled water  upto  5 minutes. 
 
Antigen Retrieval: 
1. Heat induced antigen retrieval was done with microwave oven in 
appropriate temperature with appropriate buffer for 20 minutes. This 
step unmasks the antigenic determinants of fixed tissue sections. 
2. The slides were then cooled to room temperature for 20 minutes and 
washed with tap water for 5 minutes. 
3. The slides were then rinsed with  distilled water for 5 minutes. 
4. then the slides were washed with appropriate wash buffer (phosphate 
buffer) for 5 minutes x 2 changes. 
5. Peroxidase block was then applied  for 10 minutes. 
6. The slides then were washed in phosphate buffer for 5 minutes x 2 
changes. 
7. Sections were covered with protein block for 5 minutes. 
 
 
 
  
Antibody application: 
1. The sections were drained (without washing) and appropriate primary 
antibody is applied and incubated for 30 minutes. 
2. The slides were washed in the phosphate buffer for 5 minutes x 2 
changes. 
3. The slides were covered with Primary antibody amplifier for 10 
minutes. 
4. The slides were washed in the phosphate buffer for 5 minutes x 2 
changes. 
5. The slides were covered with HRP micropolymer Quanto for 10 
minutes. 
6. The slides were washed in the phosphate buffer for 5 minutes x 2 
changes. 
 
Chromogen application: 
1. DAB substrate was prepared by diluting 1 drop of DAB Quanto 
chromogen to 1 ml of DAB Quanto buffer. 
2. DAB substrate solution was applied on the sections for 5 minutes. 
3. Wash the slides then in distilled water for 2 minutes. 
4. counterstain the section with Hematoxylin  for 2 seconds. 
5. Wash the slides in running tap water for 5 minutes. 
6. Air dry the slides, cleared with xylene and mounted with DPX. 
 
Alternate methods of antigen retrieval 
• Pressure cooker antigen retrieval 
• Microwave and trypsin antigen retrieval 
 
 
 
 
ANNEXURE IV 
PROFORMA 
 
Name    :  
Age     : 
IP Number   : 
Biopsy No   : 
Presenting symptoms :  post-menopausal bleeding/white  
 discharge/abdominal pain 
Parity :  parous/nulliparous 
Menstrual status  :   menstruating/ post-menopausal 
Ultrasound findings : 
CT findings   : 
Clinical diagnosis  : 
Fractional curettage : 
Type of specimen  :    hysterectomy 
Gross    :   proliferative/infiltrative 
Microscopy  : Histological diagnosis according to   
                                             WHO classification 
IHC (TTF 1 expression) :   negative/ focal/diffuse 
  
ANNEXURE V 
INFORMATION SHEET 
Title :  A study of expression of Thyroid transcription factor(TTF-    1) in 
endometrial adenocarcinoma of uterine corpus 
• Your specimen has been accepted. 
• We are conducting a study on Uterine endometrial  adeno 
carcinoma among patients attending Institute of Obstetrics & 
Gynaecology, Hospital, Chennai and for that your specimen may be 
valuable to us. 
• The purpose of this study is to diagnose the expression of a special 
marker (TTF-1) in uterine endometrial adenocarcinoma. 
• We are selecting certain cases and if your specimen is found 
eligible, we may be using your specimen to perform extra tests and 
special studies which in any way do not affect your final report or 
management. 
• The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or 
presentation resulting from the research, no personally identifiable 
information will be shared. 
• Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; 
your decision will not result in any loss of benefits to which you are 
otherwise entitled. 
• The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found 
abnormal which may aid in the management or treatment. 
 
Signature of investigator     Signature of participant 
 
Date:  
Bªê©a] uP¶µ uêÇ 
 
Bªê©a] uí°œ™ : P¯–œí– ™ÍËì{ê¥µ ]Èœ™ SÉ¦k (TTF1) uÔí©í¤  
   PshÉuµ. 
 
B©¶êÂ¯    : ©−. M. —−•uê 
ì{ê©SÉ¥¤µ xíÈ, 
ë\ÔíÏ ©−zx¶U Pµ´«, 
ë\ÔíÏ & 600003. 
 
u[PÂx P¯–œí– ™ÍËì{ê© Pmi (AËí¶ ]Qaí\ ë\©¤œ–mh 
Pmi) C[S ë–ÍËU ëPêÇÂœ–mhx. 
 
ë\ÔíÏ ©Pœì–Ë ©ÍË£ ©PÃ¯ ì{ê¥¤µ |í°¤£ 
©−zx¶©íÏUS ¶−£ ì{ê¤êÃPÃh£ C−US£ P¯–œí– ™ÍËì{ê© 
PmiPíÂœ –ÍÉ¤ J− Bªê©a] C[S {íhë–ÍË ¶−QÔÈx. 
 
P¯–œí– ™ÍËì{ê© Pmi¥µ ]Èœ™ SÉ¦k (TTF1) ë\©x AuÔ 
uÔí©í¤ PshÉ•x Bªê¤ ¡i§£ GÔ–ìu C•u Bªê©a]¥Ô 
ì{êUP©êS£. 
 
}[PÅ£ C•u Bªê©a]¥µ –[ìPÍP {ê[PÇ ·−£™QìÈê£. C•u 
Bªê©a]¥µ E[PÅíh¤ v_UPíÂ Gkzx ]° ]Èœ™œ –«ì\êuíÏUS 
Em–kzv AuÔ uP¶µPíÂ Bªê©ì¶ê£. AuÏêµ u[PÂx ì{ê¥Ô 
B©¶ÉUíPì¤ê Aµ°x ]Qaí\ì¤ê –êvœ™USÇÂêPêx GÔ–íu§£ 
ëu«·zxU ëPêÇQìÈê£. 
 
¡i¹PíÂ Aµ°x P−zxPíÂ ë¶Ã¥k£ ì–êìuê Aµ°x 
Bªê©a]¥Ô ì–êìuê u[PÂx ë–¤íªì¤ê Aµ°x Aíh¤êÂ[PíÂì¤ê 
ë¶Ã¥h ©êmìhê£ GÔ–íu§£ ëu«·zxU ëPêÇQìÈê£. 
 
C•u Bªê©a]¥µ –[ìPÍ–x u[PÅíh¤ ·−œ–zvÔ ì–«µ uêÔ 
C−UQÈx. ì©³£ }[PÇ G•ì{ª¡£ C•u Bªê©a]¥µ C−•x 
—Ô¶ê[P°ê£ GÔ–íu§£ ëu«·zxU ëPêÇQìÈê£. 
 
 C•u ]Èœ™œ –«ì\êuíÏPÃÔ ¡i¹PíÂ Bªê©a]¥Ô ì–êx 
Aµ°x Bªê©a]¥Ô ¡i·Ô ì–êx u[PÅUS AÉ·œì–ê£ GÔ–íu§£ 
ëu«·zxU ëPêÇQìÈê£. 
 
C•u B©í¶ –ÍÉ¤ \•ìuP[PÅUS ëuêh¯™ ëPêÇÂ ì¶si¤¶¯ : 
©−. M.—−•uê. ë\µ : 9488382773 
 
 
 
–[ìPÍ–êÂ¯ íPë¤êœ–£..................................................... Ch£ :............. ìuv :...................... 
–[ìPÍ–êÂ¯ ë–¤¯ ©ÍË£ ·°ê\£ ........................................................................................... 
Bªê©a]¤êÂ¯ íPë¤êœ–£................................................... Ch£ :............. ìuv :...................... 
 
 
 
 
 
 
 
                                         
INFORMED CONSENT FORM 
 
Title of the study   : A STUDY OF EXPRESSION OF THYROID TRANSCRIPTION FACTOR 
(TTF1) IN 
   ENDOMETRIAL ADENOCARCINOMA OF UTERUS. 
 
Name of the Participant : 
Name of the Principal (Co-Investigator) :  
Name of the Institution : Institute of obstetrics and gynaecology, Madras Medical College. 
Name and address of the sponsor / agency (ies) (if any) : 
 
Documentation of the informed consent 
 
I _____________________________ have read the information in this form (or it has been 
read to me). I was free to ask any questions and they have been answered. I am over 18 
years of age and, exercising my free power of choice, hereby give my consent to be included 
as a participant in 
“A STUDY OF EXPRESSION OF THYROID TRANSCRIPTION FACTOR IN  ENDOMETRIAL 
ADENO- 
CARCINOMA OF UTERINE CORPUS” 
 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study in which the resected endometrial 
tumors will be subjected to immunohistochemistry and histopathological examination. 
4. I have been explained about my rights and responsibilities by the investigator. I have the 
right to withdraw from the study at any time. 
5. I have been informed the investigator of all the treatments I am taking or have taken in 
the past ________ months including any native (alternative) treatment.  
6. I hereby give permission to the investigators to release the information obtained from 
me as result of participation in this study to the sponsors, regulatory authorities, Govt. 
agencies, and IEC. I understand that they are publicly presented. 
7. I have understand that my identity will be kept confidential if my data are publicly 
presented 
8. I have had my questions answered to my satisfaction. 
9. I have decided to be in the research study. 
 
I am aware that if I have any question during this study, I should contact the investigator. By 
signing this consent form I attest that the information given in this document has been 
clearly explained to me and understood by me, I will be given a copy of this consent 
document. 
 
For adult participants: 
Name and signature / thumb impression of the participant (or legal representative if 
participant 
incompetent) 
Name _________________________ Signature_________________ 
Date________________ 
 
Name and Signature of impartial witness (required for illiterate patients): 
 
Name _________________________ Signature_________________ 
Date________________ 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent: 
 
Name _________________________ Signature_________________ 
Date________________  
 Bªê©a] Jœ™uµ Piu£ 
 
 
Bªê©a] uí°œ™ : P¯–œí– ™ÍËì{ê¥µ ]Èœ™ SÉ¦k (TTF1) uÔí©í¤  
   PshÉuµ. 
 
 ë\ÔíÏ ©−zx¶U Pµ´« ì{ê©SÉ¥¤µ xíÈ¥µ  –¥³£ 
¡xPí° ©−zx¶¯ M. —−•uê, A¶¯PÇ ì©ÍëPêÇÅ£ C•u B©·µ 
–[SëPêÇÂ ............................................................ BQ¤ {êÔ ¡¿ ©ÏxhÔ 
\£©vUQìÈÔ. 
 
 GÏUS ·ÂUPœ–mh ·Ú¤[PíÂ {êÔ ™«•x ëPêsk {êÔ GÏx 
\£©uzíuz ëu«·UQìÈÔ. 
 
 C•u Bªê©a]¥µ —È«Ô |¯œ–•uŸÔÉ GÔ ë\ê•u ·−œ–zvÔ 
ì–«µ uêÔ –[S ë–ËQìÈÔ ©ÍË£ {êÔ C•u Bªê©a]¥±−•x 
G•ì{ª¡£ —Ô¶ê[P°ê£ GÔ–íu§£ AuÏêµ G•u –êvœ™£ HÍ–hêx 
GÔ–íu§£ {êÔ ™«•x ëPêsìhÔ. 
 
 {êÔ P¯–œí– ™ÍËì{ê© Pmi ì{ê©PÇ SÉzu C•u Bªê©a]¥Ô 
·¶ª[PíÂU ëPêsh uP¶µ uêíÂœ ë–ÍËU ëPêsìhÔ. 
 
 {êÔ GÔÒíh¤ _¤|íÏ¹hÔ ©ÍË£ ¡¿ _u•vªzxhÔ C•u 
©−zx¶ Bªê©a]¥µ GÔíÏ ì\¯zxU ëPêÇÂ \£©vUQìÈÔ. 
 
 GÏUS AËí¶ ]Qaí\ ë\©¤œ–mk ì{ê©USÉ¥¤µ xíÈ¥µ 
\íuœ –«ì\êuíÏUS –¤Ô–mh ë©¿SUPmiPíÂ í¶zx Bªê©a] 
©ÍË£ ]Èœ™œ –«ì\êuíÏ ë\©¤x ëPêÇÂ \£©u£ ëu«·UQìÈÔ. 
 
 
 
 
–[ìPÍ–êÂ¯ íPë¤êœ–£..................................................... Ch£ :............. ìuv :...................... 
–[ìPÍ–êÂ¯ ë–¤¯ ©ÍË£ ·°ê\£ ........................................................................................... 
 
Bªê©a]¤êÂ¯ íPë¤êœ–£................................................... Ch£ :............. ìuv :...................... 
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MASTER CHART 
MASTER CHART - I 
S.NO BX.NO AGE P/NP menstrual status C.F F.C STA. LAP GRADE FIGO STAGE TYPE 
1 412/10 59 P 3 1 Anaplastic Undiff ca NA IIIB 2 
2 474/10 40 P 1 2 Well diff Well diff 1 IA 1 
3 620/10 50 P 2 2,3 Well diff Well diff 1 IIIA 1 
4 671/10 62 P 3 1 Poor diff Poor diff 3 IB 2 
5 724/10 62 P 3 1 Well diff Well diff 1 IB 1 
6 797/10 70 P 3 1 Clear ca Clear ca NA IB 2 
7 844/10 63 NP 3 1 Well diff Well diff 1 IB 1 
8 1193/10 50 P 2 2,4 Poor diff Poor diff 3 II 2 
9 1302/10 78 NP 3 1 Poor diff Poor diff 3 IIIA 2 
10 2412/10 52 P 2 2 Mod diff Mod diff 2 IIIC1 1 
11 2535/10 65 P 3 1 Well diff Well diff 1 II 1 
12 2581/10 45 NP 2 2 Well diff Well diff 1 IA 1 
13 2621/10 45 P 2 2 Well diff Well diff 1 IA 1 
14 2767/10 63 P 3 1 Mod diff Mod diff 2 IIIC2 1 
15 2845/10 48 NP 2 2 Well diff Well diff 1 IA 1 
16 3103/10 56 P 3 1 Mod diff Mod diff 2 IA 1 
17 3048/10 50 P 2 2 Mod diff Mod diff 2 IA 1 
18 58/11 50 P 2 2 Well diff Mod diff 2 IA 1 
19 326/11 55 NP 3 1 Serous ca Serous ca NA IB 2 
20 428/11 56 NP 3 1 Well diff Well diff 1 IIIA 1 
21 550/11 70 P 3 1 Mod diff Mod diff 1 IB 1 
22 1049/11 60 P 3 1 Well diff Well diff 1 IA 1 
23 1250/11 34 NP 1 2 Well diff Well diff 1 IA 1 
24 1559/11 65 P 3 1,3 MMMT MMMT NA IA 2 
25 2055/11 50 P 2 2 Poor diff Poor diff 3 II 2 
26 2254/11 61 P 3 1 Well diff Well diff 1 IA 1 
27 2288/11 60 P 3 1 Mod diff Poor diff 3 II 2 
28 2289/11 53 P 2 2 Mod diff Poor diff 3 IB 2 
29 2358/11 58 P 3 1 Well diff Well diff 1 IB 1 
30 2638/11 68 P 3 1 Well diff Well diff 1 IA 1 
31 2730/11 46 P 2 2 Well diff Well diff 1 IA 1 
32 2969/11 41 P 2 2 Well diff Well diff 1 IA 1 
33 3168/11 52 P 2 2 Well diff Well diff 1 IA 1 
34 3211/11 57 P 3 1 Well diff Well diff 1 IB 1 
35 3339/11 67 P 3 1 Well diff Mod diff 2 IB 1 
36 3461/11 57 NP 3 1 Well diff Well diff 1 IA 1 
37 17/12 70 P 3 1 Well diff Well diff 1 IB 1 
38 46/12 57 P 3 1,4 Well diff Well diff 1 IA 1 
39 349/12 45 P 2 2 Well diff Well diff 1 IA 1 
40 1463/12 40 P 1 2 Well diff Mod diff 2 IIIC1 1 
41 2198/12 55 P 3 1 Well diff Well diff 1 IA 1 
42 2268/12 70 P 3 1 Well diff Well diff 1 IA 1 
43 2388/12 55 P 3 1 Well diff Well diff 1 IB 1 
44 2400/12 45 P 2 2,4 Well diff Well diff 1 IA 1 
45 2522/12 56 NP 3 1 Poor diff Poor diff 3 IB 2 
46 2547/12 60 P 3 1 Well diff Well diff 1 IIIA 1 
47 2558/12 48 P 2 2,3 not done MMMT NA IA 2 
48 2597/12 60 P 3 1 Well diff Well diff 1 IA 1 
49 2606/12 45 NP 2 2 Mod diff Mod diff 2 IVB 1 
50 2855/12 57 P 3 1 VG ca VG ca 1 IA 1 
51 3086/12 48 P 2 2 Well diff Well diff 1 IIIC2 1 
52 SP16/13 61 P 3 1 Well diff Well diff 1 IA 1 
53 SP33/13 57 NP 3 1 Poor diff Poor diff 3 IB 2 
54 SP36/13 59 P 3 1 Well diff Well diff 1 IA 1 
55 414/13 52 P 2 2 Well diff Well diff 1 II 1 
56 660/13 46 P 2 2 Well diff Well diff 1 IA 1 
57 684/13 54 P 2 2 Well diff Well diff 1 IB 1 
58 1417/13 62 P 2 2 Well diff Well diff 1 IB 1 
59 1678/13 45 P 2 2 Well diff Well diff 1 IB 1 
60 2025/13 37 P 1 2,3 Mod diff Mod diff 2 II 1 
61 2113/13 36 P 1 2 Well diff Well diff 1 IA 1 
62 2208/13 65 P 3 1 Well diff Mod diff 2 IA 1 
63 2219/13 45 P 2 2 Well diff Well diff 1 IB 1 
64 2677/13 42 P 2 2 Poor diff Poor diff 3 II 2 
65 2813/13 40 P 1 2 Poor diff Poor diff 3 IA 2 
66 SP26/14 50 NP 2 1,3 Undiff ca Poor diff 3 not done 2 
67 63/14 57 P 3 1 Well diff Well diff 1 IA 1 
68 77/14 62 P 3 1 Well diff Well diff 1 IB 1 
69 239/14 55 P 3 1 Well diff Well diff 1 IB 1 
70 545/14 50 P 2 2 Undiff ca Poor diff 3 IA 2 
71 639/14 48 P 2 2 not done Poor diff 3 II 2 
72 671/14 55 NP 3 1 MMMT MMMT NA II 2 
73 790/14 55 P 3 1,3 Well diff Well diff 1 IA 1 
74 864/14 65 NP 3 1 Well diff Well diff 1 IB 1 
75 888/14 65 NP 3 1,3 Well diff Well diff 1 IB 1 
76 899/14 48 P 2 2 Mod diff Mod diff 2 IB 1 
77 987/14 60 P 3 1,3 Well diff Mod diff 2 IIIA 1 
78 1200/14 50 P 2 2,3 Well diff Well diff 1 IIIA 1 
79 1297/14 63 P 3 1 Well diff Well diff 1 IA 1 
80 1569/14 50 P 2 2,3,4 Clear ca Clear ca NA II 2 
81 1634/14 40 P 1 2 Poor diff Poor diff 3 II 2 
82 1670/14 47 P 2 2 Well diff Well diff 1 IA 1 
83 1798/14 42 P 2 2 Well diff Well diff 1 IB 1 
84 2032/14 62 P 3 5 not done Well diff 1 IA 1 
85 2158/14 65 P 3 1 Mod diff Mod diff 2 IB 1 
86 2186/14 65 P 3 1 Poor diff Poor diff 3 IA 2 
87 2663/14 65 P 3 1 Clear ca Clear ca NA IIIA 2 
88 2739/14 54 P 2 2 MMMT MMMT NA IA 2 
89 2838/14 60 P 3 1 Well diff Well diff 1 IA 1 
90 2873/14 58 P 3 1 Poor diff Poor diff 3 IA 2 
91 3081/14 41 P 2 2 Comp hyp Well diff 1 IA 1 
92 3168/14 27 NP 1 2 Mod diff Mod diff 2 IA 1 
93 3175/14 56 P 3 1 Well diff Well diff 1 IA 1 
 
KEY TO MASTER CHART I 
P  - parous 
NP -  nulliparous 
F.C  - fractional curettage 
 
Menstrual status: 
1   -   premenopausal  
2   - perimenopausal 
3   - postmenopausal 
 
C.F- clinical features: 
1   - postmenopausal bleeding 
2   - bleeding pv 
3  - abdominal pain 
4  - white discharge 
5   - mass descending per vagina 
Ca   - carcinoma 
Mod   - moderate 
Undiff -  undifferentiated 
Comp hyp  - complex hyperplasia with atypia 
NA   - Not applicable 
 
MASTER CHART - II 
S.NO BX.NO AGE/SEX P/NP 
menstrual 
status CF FC GROSS HPE GRADE 
FIGO 
STAGE TYPE TTF1 Tt&FOLLOWUP 
1 17/12 70 P 3 1 Well diff 1 Well diff 1 IB 1 neg RT;24 mnths 
2 349/12 45 NP 2 2 Well diff 1 Well diff 1 IA 1 neg 12 mnths 
3 1463/12 40 P 1 2 Well diff 2 Mod diff 2 IIIC1 1 neg RT, chemo;11 mnths 
4 2198/12 55 P 3 1 Well diff 1 Well diff 1 IA 1 neg 26 mnths 
5 2268/12 70 P 3 1 Well diff 1 Well diff 1 IA 1 neg 16 mnths 
6 2388/12 55 P 3 1 Well diff 1 Well diff 1 IB 1 neg RT;16 mnths 
7 2522/12 56 NP 3 1 Poor diff 1 Poor diff 3 IB 2 neg RT;26 mnths 
8 2547/12 60 P 3 1 Well diff 1 Well diff 1 IIIA 1 neg - 
9 2558/12 48 P 2 2,3 MMMT 1 MMMT NA IA 2 neg - 
10 2597/12 60 P 3 1 Well diff 1 Well diff 1 IA 1 neg 21 mnths 
11 2606/12 45 NP 2 2 Mod diff 2 Mod diff 2 IVB 1 neg chemo; 5 mnths 
12 2855/12 57 P 3 1 Well diff 1 Well diff 1 IA 1 neg 28 mnths 
13 3086/12 48 P 2 2 Well diff 2 Well diff 1 IIIC2 1 neg - 
14 SP16/13 61 P 3 1 Well diff 1 Well diff 1 IA 1 neg 12 mnths 
15 SP36/13 59 P 3 1 Well diff 1 Well diff 1 IA 1 neg - 
16 414/13 52 P 2 2 Well diff 1 Well diff 1 II 1 neg RT chemo;24 mnths 
17 660/13 46 P 2 2 Well diff 1 Well diff 1 IA 1 neg - 
18 684/13 54 P 2 2 Well diff 1 Well diff 1 IB 1 neg RT;10 mnths 
19 1678/13 45 P 2 2 Well diff 1 Well diff 1 IIIA 1 neg RT chemo 
20 2025/13 37 P 1 2,3 Mod diff 1 Mod diff 2 II 1 neg RT 
21 2113/13 36 P 1 2 Well diff 1 Well diff 1 IA 1 neg - 
22 2208/13 65 P 3 1 Well diff 1 Mod diff 2 IA 1 focal - 
23 2219/13 45 P 2 2 Well diff 1 Well diff 1 IB 1 neg RT;10 mnths 
24 2677/13 42 P 2 2 Poor diff 1 Poor diff 3 II 2 neg RT 
25 2813/13 40 P 1 2 Poor diff 1 Poor diff 3 IA 2 neg RT 
26 SP26/14 50 NP 2 2,3 Undiff ca 1 Poor diff 3 - 2 diffuse - 
27 63/14 57 P 3 1 Well diff 1 Well diff 1 IA 1 neg 12 mnths 
28 77/14 62 P 3 1 Well diff 1 Well diff 1 IB 1 neg - 
29 639/14 48 P 2 2 not done 2 Poor diff 3 II 2 neg RT 
30 671/14 55 NP 3 1 MMMT 1 MMMT NA II 2 neg k/c/o ca breast ,RT 
31 790/14 55 P 3 1,3 Well diff 1 Well diff 1 IA 1 neg 13 mnths 
32 864/14 65 NP 3 1 Well diff 1 Well diff 1 IB 1 neg RT 
33 888/14 65 NP 3 1,3 Well diff 1 Well diff 1 IB 1 neg RT; 5 mnths 
34 899/14 48 P 2 2 Mod diff 1 Mod diff 2 IB 1 neg RT;15 mnths 
35 987/14 60 P 3 1,3 Well diff 1 Mod diff 2 IIIA 1 neg RT chemo;10 mnths 
36 1200/14 50 P 2 2,3 Well diff 1 Well diff 1 IIIA 1 neg RT chemo 
37 1297/14 63 P 3 1 Well diff 1 Well diff 1 IA 1 neg 15 mnths 
38 1569/14 50 P 2 2,3,4 Clear ca 1 Clear ca NA II 2 neg RT;10 mnths 
39 1634/14 40 P 1 2 Poor diff 1 Poor diff 3 II 2 neg RT ;6 mnths 
40 1670/14 47 P 2 2 Well diff 1 Well diff 1 IA 1 neg 6 mnths 
41 1798/14 42 P 2 2 Well diff 1 Well diff 1 IB 1 neg RT 
42 2032/14 62 P 3 5 not done 1 Well diff 1 IA 1 neg 6 mnths 
43 2158/14 65 P 3 1 Mod diff 1 Mod diff 2 IB 1 focal RT; 7 mnths 
44 2663/14 65 P 3 1 Clear ca 1 Clear ca NA IIIA 2 neg ca breast, RT 
45 2739/14 54 P 2 2 MMMT 1 MMMT NA IA 2 neg ca breast, RT 
46 2838/14 60 P 3 1 Well diff 2 Well diff 1 IA 1 neg - 
47 2873/14 58 P 3 1 Poor diff 1 Poor diff 3 IA 2 neg 6 mnths 
48 3081/14 41 P 2 2 Comp hyp 1 Well diff 1 IA 1 neg - 
49 3168/14 27 NP 1 2 Mod diff 1 Mod diff 2 IA 1 neg - 
50 3175/14 56 P 3 1 Well diff 1 Well diff 1 IA 1 neg 4 mnths 
 
KEY TO MASTER CHART 2 
P – parous 
NP- nulliparous 
F.C – fractional curettage 
 
Menstrual status: 
1  -   premenopausal  
2  - perimenopausal 
3  -  postmenopausal 
 
C.F- clinical features 
1  - postmenopausal bleeding 
2 - bleeding pv 
 3 - abdominal pain 
 4 - white discharge 
 5  - mass descending per vagina 
 
Gross : 
1 - Proliferative growth 
2 - Infiltrative growth 
Ca  - carcinoma 
Mod  - moderate 
Undiff -  undifferentiated 
Com hyp  -  complex hyperplasia with atypia 
RT   - radiotherapy 
Chemo  - chemotherapy 
Mnths  - months  
 
TTF 1 : 
Neg   - Negative 
Focal   -   less than 50%  positive 
Diffuse  -  more than 50% positive  
 
